Risk factor
Very high price volatility
Profitability factor
Very low or no dividends
About
Virax Biolabs Group Limited is a biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. The company is developing T cell-based test technologies intended to support an immunology profiling platform, with potential applications in post-acute infection syndromes, including Long COVID, and other chronic conditions linked to immune dysregulation.
Company Valuation
Considering past and projected metrics, the stock is neither 'expensive' nor 'cheap' compared to its peers. Specifically, the stock is neutral on EV/EBITDA.
Target Price
The average target price of VRAX is 1.00 and suggests 68.3% downside potential. Usually, this means a SELL recommendation among investment firms, or a recommendation to d